DK0750509T3 - Anvendelse af IL-12 og IL 12-antagonister til fremstilling af et farmaceutisk præparat til behandling af autoimmune sygdomme - Google Patents

Anvendelse af IL-12 og IL 12-antagonister til fremstilling af et farmaceutisk præparat til behandling af autoimmune sygdomme

Info

Publication number
DK0750509T3
DK0750509T3 DK95912666T DK95912666T DK0750509T3 DK 0750509 T3 DK0750509 T3 DK 0750509T3 DK 95912666 T DK95912666 T DK 95912666T DK 95912666 T DK95912666 T DK 95912666T DK 0750509 T3 DK0750509 T3 DK 0750509T3
Authority
DK
Denmark
Prior art keywords
autoimmune
preparation
treatment
antagonists
autoimmune diseases
Prior art date
Application number
DK95912666T
Other languages
English (en)
Other versions
DK0750509T4 (da
Inventor
John P Leonard
Samuel Goldman
Richard O'hara Jr
Original Assignee
Genetics Inst
Inst Genetics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22791827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0750509(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst, Inst Genetics Llc filed Critical Genetics Inst
Publication of DK0750509T3 publication Critical patent/DK0750509T3/da
Application granted granted Critical
Publication of DK0750509T4 publication Critical patent/DK0750509T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK95912666T 1994-03-14 1995-03-07 Anvendelse af IL-12 og IL 12-antagonister til fremstilling af et farmaceutisk præparat til behandling af autoimmune sygdomme DK0750509T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21262994A 1994-03-14 1994-03-14
PCT/US1995/002550 WO1995024918A1 (en) 1994-03-14 1995-03-07 Use of il-12 and il-12 antagonists in the treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
DK0750509T3 true DK0750509T3 (da) 2002-07-08
DK0750509T4 DK0750509T4 (da) 2006-10-16

Family

ID=22791827

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95912666T DK0750509T4 (da) 1994-03-14 1995-03-07 Anvendelse af IL-12 og IL 12-antagonister til fremstilling af et farmaceutisk præparat til behandling af autoimmune sygdomme

Country Status (14)

Country Link
US (1) US6338848B1 (da)
EP (4) EP1179348A3 (da)
JP (1) JP3798426B2 (da)
AT (1) ATE217533T1 (da)
AU (1) AU689236B2 (da)
CA (1) CA2185565C (da)
DE (1) DE69526728T3 (da)
DK (1) DK0750509T4 (da)
ES (1) ES2173953T5 (da)
IL (1) IL112677A (da)
PT (1) PT750509E (da)
TW (1) TW400233B (da)
WO (1) WO1995024918A1 (da)
ZA (1) ZA95960B (da)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780597A (en) 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
US6830751B1 (en) * 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
US20010055581A1 (en) * 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
PT936923E (pt) * 1996-11-15 2004-04-30 Kennedy Inst Of Rheumatology Supressao de tnfalfa e il-12 em terapia
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
ES2284242T3 (es) 1998-01-23 2007-11-01 F. Hoffmann-La Roche Ag Anticuerpos contra il-12 humana.
WO2000034459A1 (en) * 1998-12-09 2000-06-15 Protein Design Labs, Inc. Animal model for psoriasis for the prevention and treatment of psoriasis in humans
EP1176140B1 (en) 1999-02-10 2004-12-29 Mitsubishi Pharma Corporation Amide compounds and medicinal use thereof
AU2005200515B2 (en) * 1999-03-25 2006-07-13 AbbVie Deutschland GmbH & Co. KG Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
EP2168984B1 (en) * 1999-03-25 2012-08-29 Abbott GmbH & Co. KG Human antibodies that bind human IL-12 and methods for producing
JP4676049B2 (ja) * 1999-07-21 2011-04-27 生化学工業株式会社 Ｉｌ−１２産生抑制剤
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
US8080247B2 (en) 2000-08-07 2011-12-20 Janssen Biotech, Inc. Anti-IL-12 antibodies
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
EP1494710A4 (en) * 2002-03-26 2007-03-21 Centocor Inc DIABETES-RELEVANT IMMUNOGLOBULIN-BASED PROTEINS, COMPOSITIONS, PROCESSES AND USES
WO2005065121A2 (en) 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
US20070178520A1 (en) * 2004-02-27 2007-08-02 Barbara Wolff-Winiski Screening assay for modulators of interaction between interleukin-12 and/or -23 with their receptors
DK2299275T3 (da) * 2004-07-30 2018-05-07 Adeza Biomedical Corp Klassificering af onkoføtalt fibronectin niveau for graviditetsrelaterede indikationer
EP2500355A3 (en) 2005-08-19 2012-10-24 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1928506A4 (en) 2005-08-19 2009-10-21 Abbott Lab IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
RU2475265C2 (ru) 2007-01-16 2013-02-20 Эбботт Лэборетриз Способы лечения псориаза
KR20100014674A (ko) 2007-03-29 2010-02-10 아보트 러보러터리즈 결정성 항-사람 ｉｌ-12 항체
TW201513883A (zh) 2008-03-18 2015-04-16 Abbvie Inc 治療牛皮癬的方法
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
MX2010013236A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
US20110243938A1 (en) * 2008-09-30 2011-10-06 Baylor Research Intitute Methods to Reduce B-Helper T Cells to Treat Autoimmune Diseases
CN104398471A (zh) * 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
PE20121530A1 (es) 2009-09-01 2012-12-22 Abbvie Inc Inmunoglobulinas con dominio variable dual
MX2012003138A (es) 2009-09-14 2012-07-04 Abbott Lab Y Abbott Gmbh & Co Kg Metodos para tratar la psoriasis.
US8716450B2 (en) 2009-10-15 2014-05-06 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
RU2013109275A (ru) 2010-08-03 2014-09-10 Эббви Инк. Иммуноглобулины с двумя вариабельными доменами и их применение
KR20130139884A (ko) 2010-08-26 2013-12-23 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
US8962317B2 (en) 2010-09-28 2015-02-24 Neumedicines, Inc. Uses of IL-12 and the IL-12 receptor positive cell in tissue repair and regeneration
US8853365B2 (en) 2010-12-21 2014-10-07 Abbvie Inc. Dual variable domain immunnoglobulins and uses thereof
NO2709651T3 (da) 2011-05-19 2018-03-03
CA2843014C (en) * 2011-07-27 2020-01-21 Neumedicines, Inc. Use of il-12 to generate endogenous erythropoietin
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
RU2017137740A (ru) 2012-11-01 2019-02-11 Эббви Инк. Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
BR112015023797A2 (pt) 2013-03-15 2017-10-24 Abbvie Inc proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
BR112018069776A2 (pt) 2016-03-29 2019-02-05 Janssen Biotech Inc tratamento de psoríase com intervalo de dosagem aumentado de anticorpos anti-il-12 e/ou anti-il-23
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US11578124B2 (en) 2018-05-18 2023-02-14 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-IL12/IL23 antibody
FI3883606T3 (fi) 2018-09-24 2023-09-07 Janssen Biotech Inc Turvallinen ja tehokas menetelmä haavaisen paksusuolitulehduksen hoitamiseksi anti-il12/il23-vasta-aineella
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
ATE366311T1 (de) * 1989-12-22 2007-07-15 Hoffmann La Roche Zytotoxischer lymphozyten-reifefaktor 35kd untereinheit und monoklonale antikörper spezifisch dafür
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
EP0638644A1 (en) * 1993-07-19 1995-02-15 F. Hoffmann-La Roche Ag Receptors of interleukin-12 and antibodies
US5536657A (en) * 1993-07-19 1996-07-16 Hoffmann-La Roche Inc. Recombinant DNA encoding human receptor for interleukin-12
US5853721A (en) * 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor
CN1300173C (zh) * 1996-02-09 2007-02-14 艾博特生物技术有限公司 结合人TNFα的人抗体
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
ID22975A (id) * 1997-03-18 1999-12-23 Basf Ag Metode dan komposisi untuk memodulasi respons terhadap kortikosteroid
ES2284242T3 (es) * 1998-01-23 2007-11-01 F. Hoffmann-La Roche Ag Anticuerpos contra il-12 humana.
US8700033B2 (en) 2008-08-22 2014-04-15 International Business Machines Corporation Dynamic access to radio networks
CN102377479B (zh) 2010-08-11 2015-01-21 华为技术有限公司 数据同步方法及系统、光网络单元

Also Published As

Publication number Publication date
ES2173953T5 (es) 2007-03-01
IL112677A0 (en) 1995-05-26
AU1974995A (en) 1995-10-03
DE69526728T2 (de) 2002-11-21
TW400233B (en) 2000-08-01
IL112677A (en) 2000-01-31
EP0750509B1 (en) 2002-05-15
DE69526728T3 (de) 2007-01-04
ES2173953T3 (es) 2002-11-01
JP3798426B2 (ja) 2006-07-19
PT750509E (pt) 2002-08-30
AU689236B2 (en) 1998-03-26
EP0750509B2 (en) 2006-06-14
EP1179348A3 (en) 2003-12-03
US6338848B1 (en) 2002-01-15
EP0750509A1 (en) 1997-01-02
DE69526728D1 (de) 2002-06-20
CA2185565A1 (en) 1995-09-21
ATE217533T1 (de) 2002-06-15
CA2185565C (en) 2009-02-03
EP2201959A2 (en) 2010-06-30
DK0750509T4 (da) 2006-10-16
WO1995024918A1 (en) 1995-09-21
EP2311484A1 (en) 2011-04-20
JPH09510444A (ja) 1997-10-21
ZA95960B (en) 1995-10-10
EP1179348A2 (en) 2002-02-13
EP2201959A3 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
DK0750509T4 (da) Anvendelse af IL-12 og IL 12-antagonister til fremstilling af et farmaceutisk præparat til behandling af autoimmune sygdomme
Saxne et al. Difference in cartilage proteoglycan level in synovial fluid in early rheumatoid arthritis and reactive arthritis
ATE411029T1 (de) Estrogene als antimitotika
ATE183087T1 (de) Verwendung von beta-hydroxy-beta- methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen
IT1212892B (it) Acido ialuronico ottenuto per mezzodi filtrazione molecolare sprovvisto di attivita' infiammatoria e sua utilizzazione terapeutica
WO1994007535A3 (en) Labelled interleukin-8 and medical uses thereof
DE69022501D1 (de) Verwendung eines Amylinantagonisten zur Herstellung eines Artzneimittels zur Behandlung von Fettsucht und essentieller Hypertonie und damit zusammenhängenden Krankheiten.
DK399288A (da) Dobbeltstrenget rna-korrektion af abnormiteter i cirkulerende immunkomplekser og monocytfunktion
FR2656214B1 (fr) Cadre dynamique d'osteosynthese du rachis.
IT1238825B (it) Dispositivo per la correzione chirurgica dell'ametropia.
DK0413329T3 (da) 5-methyl-isoxazol-4-carboxylsyreanilider og 2-hydroxyethyliden-cyaneddikesyreanilider til behandling af øjensygdomme
NO177148C (no) Fluorelastomerer basert på vinylidenfluorid, heksafluorpropen og tetrafluoretylen, samt anvendelse av slike
Rosenbaum Treating hair pulling in a 7-year-old male: Modified habit reversal for use in pediatric settings
OA08298A (fr) Nouvelles N-(aminométhyl-5 oxazolin-2 yl-2) N'-phénylurées, leur méthode de préparation ainsi que leur application thérapeutique.
Finnerty-Fried Adapting rehabilitation counseling for older persons.
Sakamoto et al. A Case Report of Multiple Tendon Xanthomas
DE69103294T2 (de) Verwendung der 3-Oxygermylpropionsäure zur Behandlung und Prävention von Diabetes verursacht durch Autoimmunkrankheiten.
Himle et al. Recent research on social support and burnout: Implications for behavior therapy.
Warning JOURNAL OF THE AMERICAN DENTAL SOCIETY OF ANESTHESIOLOGY
IT8421534A0 (it) Esteri dell'acido acetico eterociclici e relativo procedimento di fabbricazione.
Bonnie Rogers National Center for Nursing Research
IT7924227A0 (it) Metodo per la terapia dell'artrite reumatoide e formulazioni farmaceutiche idonee allo scopo.
Dolapchieva Computer-Assisted Morphometric Study on the Axons and Myelin Sheaths Areas of Developing Myelin Fibres in Peripheral Nerves of the Rabbit
Dixon The age of Cimon: the Delian League's foundation and early history
Tohyama et al. Long-Term Functional Prognosis and CT Findings of Patients with Crush Syndrome from the Hanshin-Awaji Earthquake